Bio-TechneTECHEarnings & Financial Report
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Revenue
$297.0M
Gross Profit
$193.9M
Operating Profit
$47.4M
Net Profit
$34.9M
Gross Margin
65.3%
Operating Margin
16.0%
Net Margin
11.7%
YoY Growth
9.0%
EPS
$0.22
Bio-Techne Q2 FY2025 Financial Summary
Bio-Techne reported revenue of $297.0M (up 9.0% YoY) for Q2 FY2025, with a net profit of $34.9M (up 27.0% YoY) (11.7% margin). Cost of goods sold was $103.1M, operating expenses totaled $146.5M.
Key Financial Metrics
| Total Revenue | $297.0M |
|---|---|
| Net Profit | $34.9M |
| Gross Margin | 65.3% |
| Operating Margin | 16.0% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Bio-Techne Q2 FY2025 revenue of $297.0M breaks down across 9 segments, led by Diagnostics And Spatial Biology at $84.1M (28.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Diagnostics And Spatial Biology | $84.1M | 28.3% |
| EMEA Excluding UK | $70.4M | 23.7% |
| Other | $42.1M | 14.2% |
| Instruments | $30.9M | 10.4% |
| Services | $27.4M | 9.2% |
| APAC Excluding Greater China | $19.0M | 6.4% |
| GB | $13.2M | 4.5% |
| Royalty | $8.1M | 2.7% |
| Other Revenues From Business Held For Sale | $1.8M | 0.6% |
Bio-Techne Annual Revenue by Year
Bio-Techne annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.2B |
| 2024 | $1.2B |
Bio-Techne Quarterly Revenue & Net Profit History
Bio-Techne results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2026 | $311.4M | -1.5% | $51.0M | 16.4% |
| Q2 FY2026 | $295.9M | -6.4% | $38.0M | 12.8% |
| Q4 FY2025 | $317.0M | +3.5% | $-17.7M | -5.6% |
| Q3 FY2025 | $316.2M | +4.2% | $22.6M | 7.1% |
| Q2 FY2025 | $297.0M | +9.0% | $34.9M | 11.7% |
| Q1 FY2025 | $289.5M | +4.5% | $33.6M | 11.6% |
| Q4 FY2024 | $306.1M | +1.6% | $40.6M | 13.3% |
| Q3 FY2024 | $303.4M | +3.2% | $49.1M | 16.2% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $303.4M | $306.1M | $289.5M | $297.0M | $316.2M | $317.0M | $295.9M | $311.4M |
| YoY Growth | 3.2% | 1.6% | 4.5% | 9.0% | 4.2% | 3.5% | -6.4% | -1.5% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.72B | $2.70B | $2.74B | $2.67B | $2.64B | $2.56B | $2.52B | $2.55B |
| Liabilities | $706.8M | $635.0M | $597.4M | $591.9M | $626.2M | $639.1M | N/A | $465.3M |
| Equity | $2.01B | $2.07B | $2.14B | $2.08B | $2.02B | $1.92B | $2.01B | $2.09B |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $81.0M | $75.5M | $63.9M | $84.3M | $41.1M | $98.2M |